← Leaderboards
Mark Ellis Molitch
Northwestern University
$6,998,667
Attributed
$6,998,667
Total exposure
14
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $535K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$6,998,667 · 14
By mechanism
U01$6,820,828 · 2
M01$177,839 · 12
Top collaborators
No co-investigators on record.
Most similar at Northwestern University
Same institution · by research overlap
- Raymond J Kim$4,148,381
- Keith A Horvath$683,819
- Daniel Batlle$5,645,633
- Robert O Bonow$1,979,188
- Debiao Li$36,112,049
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchDiabetes MellitusMetforminCardiovascular Disorder RiskAtherosclerosisPlacebosCardiovascular DiseasesPreventRisk FactorsLifestyle InterventionCohortDiabetes Prevention ProgramLong-Term EffectsEpidemiologyIncidenceGenotypeNon-Insulin-Dependent Diabetes MellitusLife StylePhenotypeHuman Therapy EvaluationFollow-UpDiabetes PreventionAffect
Grant awards (38)
10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project$391,248
U01 · FY2018 · DK · contact PI
10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project$324,075
U01 · FY2017 · DK · contact PI
10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project$233,941
U01 · FY2016 · DK · contact PI
10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project$45,879
U01 · FY2016 · DK · contact PI
10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project$27,550
U01 · FY2016 · DK · contact PI
DPPOS Follow-up$309,000
U01 · FY2015 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$413,362
U01 · FY2014 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$470,616
U01 · FY2013 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$433,214
U01 · FY2012 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$535,010
U01 · FY2011 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$498,616
U01 · FY2010 · DK · contact PI
Nocturnal Hypertension and Prevention of Microalbuminuria in Type I Diabetics$1,000
U01 · FY2010 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$498,616
U01 · FY2009 · DK · contact PI
Post-DPP Follow-up Study$487,470
U01 · FY2008 · DK · contact PI
Post-DPP Follow-up Study$255,289
U01 · FY2007 · DK · contact PI
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC)$17,822
M01 · FY2007 · RR · contact PI
Post-DPP Follow-up Study$356,860
U01 · FY2006 · DK · contact PI
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC)$20,273
M01 · FY2006 · RR · contact PI
Post-DPP Follow-up Study$439,539
U01 · FY2005 · DK
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC)$17,037
M01 · FY2005 · RR
DCCT/EDIC GENETIC STUDIES PROTOCOL$1,381
M01 · FY2005 · RR
Post-DPP Follow-up Study$437,169
U01 · FY2004 · DK
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)$66,368
M01 · FY2004 · RR
Epidemiology of Diabetes Interventions and Complications (EDIC)$19,520
M01 · FY2004 · RR
Hormonal, Visual, and Neuropsychologic Dysfunction in Pituitary Disease$14,314
M01 · FY2004 · RR
Diabetes Control and Complications Trial (DCCT)$650
M01 · FY2004 · RR
Post-DPP Follow-up Study$435,011
U01 · FY2003 · DK
PRIMARY PREVENTION TRIAL (DPT-2)$227,363
U01 · FY2002 · DK
HORMONAL,VISUAL &NEUROPSYCHOLOGIC DYSFUNCTION IN PITUITARY HYPOTHALAMIC DISEASE$0
M01 · FY2001 · RR
Open label trial of sandostatin LAR in acromegaly$0
M01 · FY2001 · RR
Pharmacokinetics of clinical and commercial lots of testoderm TTS product$0
M01 · FY2001 · RR
SAFETY AND EFFICACY OF SOMATOSTATIN ANALOG - Lanreotide (IPSSTYL) FOR ACROMEGALY$0
M01 · FY2001 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC)$0
M01 · FY2001 · RR
HORMONAL,VISUAL &NEUROPSYCHOLOGIC DYSFUNCTION IN PITUITARY HYPOTHALAMIC DISEASE$20,474
M01 · FY2000 · RR
Open label trial of sandostatin LAR in acromegaly$0
M01 · FY2000 · RR
Pharmacokinetics of clinical and commercial lots of testoderm TTS product$0
M01 · FY2000 · RR
SAFETY AND EFFICACY OF SOMATOSTATIN ANALOG - Lanreotide (IPSSTYL) FOR ACROMEGALY$0
M01 · FY2000 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC)$0
M01 · FY2000 · RR